Johnson & Johnson’s Dividend Performance
Johnson & Johnson is well-known for having one of the strongest dividend records among publicly traded companies in the US. It generates substantial cash flow, which supports its ability to pay out dividends consistently.
The company has set some ambitious multi-billion dollar targets for certain products. While many stocks just offer regular payments, there are those that not only maintain but also increase their dividends each year, effectively putting more cash into the pockets of shareholders. Johnson & Johnson, tagged as JNJ, belongs to this elite class.
Often referred to as a Dividend King, J&J is part of a select group of US companies that have raised dividends for at least 50 consecutive years. In fact, last April marked the 63rd consecutive year that J&J increased its dividend.
So, what can we expect moving forward? It’s reasonable to believe J&J will continue to pay larger dividends annually. With a diverse portfolio, a strong pipeline, and a solid financial foundation, the outlook seems bright.
After divesting its consumer health brands like Tylenol and Neutrogena, J&J is now focused on healthcare, particularly in areas of medicine and technology. They have over 26 products across their platforms that each bring in over $1 billion in sales, driving significant revenue and cash flow.
As for growth and research, the company spent $17 billion on R&D in 2024, and the dividend payout was $11.8 billion. Within their innovative drug segment, J&J aims to be a leader in oncology, aspiring for $50 billion in sales. Products like Darzalex and Carvykti are crucial to this goal. Additionally, their recent acquisition of a company specializing in antipsychotic therapy for $14.6 billion has introduced another product expected to generate $5 billion in sales. On the medical technology side, robotic surgeries and cardiovascular solutions are key growth areas.
Today, J&J stands as one of the largest medical firms in the US. Its unique combination of size, disciplined investments in R&D, stable cash generation, extensive pipelines, and over 60 years of continuous dividend increases paints it as a strong candidate for income-focused investors. The stock currently offers a yield of 2.9%.
If you’re considering investing in Johnson & Johnson, however, it’s worth noting that some analysts have highlighted other stocks they believe could be more attractive options right now.
The analyst team from a financial advisory service has identified a shortlist of stocks that they believe offer better potential returns than Johnson & Johnson at this moment. These stocks might present significant opportunities over the next few years.
It’s an interesting landscape, and while J&J remains a stalwart in the dividend space, investors might find it beneficial to look around before making a decision.
